| IFN regulatory factor-1 bypasses IFN-mediated antiviral effects through viperin gene induction A Stirnweiss, A Ksienzyk, K Klages, U Rand, M Grashoff, H Hauser, ... The Journal of Immunology 184 (9), 5179-5185, 2010 | 141 | 2010 |
| T cell activation results in conformational changes in the Src family kinase Lck to induce its activation A Stirnweiss, R Hartig, S Gieseler, JA Lindquist, P Reichardt, L Philipsen, ... Science signaling 6 (263), ra13-ra13, 2013 | 87 | 2013 |
| Comparative drug screening in NUT midline carcinoma AH Beesley, A Stirnweiss, E Ferrari, R Endersby, M Howlett, TW Failes, ... British journal of cancer 110 (5), 1189-1198, 2014 | 46 | 2014 |
| Novel BRD4–NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma K Thompson-Wicking, RW Francis, A Stirnweiss, E Ferrari, MD Welch, ... Oncogene 32 (39), 4664-4674, 2013 | 41 | 2013 |
| Tumor suppression by IFN regulatory factor-1 is mediated by transcriptional down-regulation of cyclin D1 A Kröger, A Stirnweiss, JE Pulverer, K Klages, M Grashoff, J Reimann, ... Cancer research 67 (7), 2972-2981, 2007 | 37 | 2007 |
| Molecular-genetic profiling and high-throughput in vitro drug screening in NUT midline carcinoma—An aggressive and fatal disease A Stirnweiss, J Oommen, RS Kotecha, UR Kees, AH Beesley Oncotarget 8 (68), 112313, 2017 | 23 | 2017 |
| A novel BRD4-NUT fusion in an undifferentiated sinonasal tumor highlights alternative splicing as a contributing oncogenic factor in NUT midline carcinoma A Stirnweiss, K McCarthy, J Oommen, ML Crook, K Hardy, UR Kees, ... Oncogenesis 4 (11), e174-e174, 2015 | 22 | 2015 |
| Targeted SMN Exon Skipping: A Useful Control to Assess In Vitro and In Vivo Splice-Switching Studies LL Flynn, C Mitrpant, A Adams, IL Pitout, A Stirnweiss, S Fletcher, ... Biomedicines 9 (5), 552, 2021 | 5 | 2021 |
| Targeting cross-presentation as a route to improve the efficiency of peptide-based cancer vaccines B Wylie, F Ong, H Belhoul-Fakir, K Priebatsch, H Bogdawa, A Stirnweiss, ... Cancers 13 (24), 6189, 2021 | 4 | 2021 |
| Novel cellular delivery methods S Stone, H Clinton, A Stirnweiss, P Cunningham US Patent App. 17/786,671, 2023 | | 2023 |
| RNA therapeutics in the treatment of retinal disease-delivering the potential S Fletcher, C Hall, M Anastasas, A Martin, T Chai, K Priebatsch, ... Investigative Ophthalmology & Visual Science 62 (8), 1196-1196, 2021 | | 2021 |
| Case Report: Long-Term Survival of a Pediatric Patient With an Intra-Abdominal Undifferentiated Carcinoma of Unknown Primary A Stirnweiss, H Dholaria, J Oommen, K Hardy, G Jevon, AH Beesley, ... Frontiers in Oncology 11, 590913, 2021 | | 2021 |
| IFN regulatory factor-1 bypasses IFN-mediated antiviral effects through viperin gene induction K Finsterbusch, A Stirnweiss, A Ksienzyk, M Grashoff, H Hauser, A Kröger | | 2011 |
| Real time monitoring of B cell antigen receptor-proximal events by fluorescence lifetime imaging M Engelke, R Hartig, I Goldbeck, B Manno, A Stirnweiß, W Zuschratter, ... Cell Communication and Signaling 7 (1), 1-1, 2009 | | 2009 |
| IRF-1-regulierte Gene: ihre Bedeutung bei der Tumorsuppression und der Abwehr viraler Infektionen A Stirnweiß Braunschweig, Techn. Univ., Diss., 2007, 2007 | | 2007 |
